Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer

Xiaoqian Xue, Yan Zhang, Chao Wang, Maofeng Zhang, Qiuping Xiang, Junjian Wang, Anhui Wang, Chenchang Li, Cheng Zhang, Lingjiao Zou, Rui Wang, Shuang Wu, Yongzhi Lu, Hongwu Chen, Ke Ding, Guohui Li, Yong Xu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The bromodomain and extra-terminal proteins (BET) have emerged as promising therapeutic targets for the treatment of castration-resistant prostate cancer (CRPC). We report the design, synthesis and evaluation of a new series of benzoxazinone-containing 3,5-dimethylisoxazole derivatives as selective BET inhibitors. One of the new compounds, (R)-12 (Y02234), binds to BRD4(1) with a Kd value of 110 nM and blocks bromodomain and acetyl lysine interactions with an IC50 value of 100 nM. It also exhibits selectivity for BET over non-BET bromodomain proteins and demonstrates reasonable anti-proliferation and colony formation inhibition effect in prostate cancer cell lines such as 22Rv1 and C4-2B. The BRD4 inhibitor (R)-12 also significantly suppresses the expression of ERG, Myc and AR target gene PSA at the mRNA level in prostate cancer cells. Treatment with (R)-12 significantly suppresses the tumor growth of prostate cancer (TGI = 70%) in a 22Rv1-derived xenograft model. These data suggest that compound (R)-12 is a promising lead compound for the development of a new class of therapeutics for the treatment of CRPC.

Original languageEnglish (US)
Pages (from-to)542-559
Number of pages18
JournalEuropean Journal of Medicinal Chemistry
Volume152
DOIs
StatePublished - May 25 2018

Fingerprint

Benzoxazines
Castration
Prostatic Neoplasms
Derivatives
Proteins
Cells
Lead compounds
Heterografts
Inhibitory Concentration 50
Lysine
Tumors
Genes
Cell Line
Messenger RNA
Therapeutics
Growth
Neoplasms

Keywords

  • 3,5-Dimethylisoxazole
  • BRD4
  • Bromodomain inhibitor
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer. / Xue, Xiaoqian; Zhang, Yan; Wang, Chao; Zhang, Maofeng; Xiang, Qiuping; Wang, Junjian; Wang, Anhui; Li, Chenchang; Zhang, Cheng; Zou, Lingjiao; Wang, Rui; Wu, Shuang; Lu, Yongzhi; Chen, Hongwu; Ding, Ke; Li, Guohui; Xu, Yong.

In: European Journal of Medicinal Chemistry, Vol. 152, 25.05.2018, p. 542-559.

Research output: Contribution to journalArticle

Xue, X, Zhang, Y, Wang, C, Zhang, M, Xiang, Q, Wang, J, Wang, A, Li, C, Zhang, C, Zou, L, Wang, R, Wu, S, Lu, Y, Chen, H, Ding, K, Li, G & Xu, Y 2018, 'Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer', European Journal of Medicinal Chemistry, vol. 152, pp. 542-559. https://doi.org/10.1016/j.ejmech.2018.04.034
Xue, Xiaoqian ; Zhang, Yan ; Wang, Chao ; Zhang, Maofeng ; Xiang, Qiuping ; Wang, Junjian ; Wang, Anhui ; Li, Chenchang ; Zhang, Cheng ; Zou, Lingjiao ; Wang, Rui ; Wu, Shuang ; Lu, Yongzhi ; Chen, Hongwu ; Ding, Ke ; Li, Guohui ; Xu, Yong. / Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer. In: European Journal of Medicinal Chemistry. 2018 ; Vol. 152. pp. 542-559.
@article{feea735c50764fb1ad4935f1789b9776,
title = "Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer",
abstract = "The bromodomain and extra-terminal proteins (BET) have emerged as promising therapeutic targets for the treatment of castration-resistant prostate cancer (CRPC). We report the design, synthesis and evaluation of a new series of benzoxazinone-containing 3,5-dimethylisoxazole derivatives as selective BET inhibitors. One of the new compounds, (R)-12 (Y02234), binds to BRD4(1) with a Kd value of 110 nM and blocks bromodomain and acetyl lysine interactions with an IC50 value of 100 nM. It also exhibits selectivity for BET over non-BET bromodomain proteins and demonstrates reasonable anti-proliferation and colony formation inhibition effect in prostate cancer cell lines such as 22Rv1 and C4-2B. The BRD4 inhibitor (R)-12 also significantly suppresses the expression of ERG, Myc and AR target gene PSA at the mRNA level in prostate cancer cells. Treatment with (R)-12 significantly suppresses the tumor growth of prostate cancer (TGI = 70{\%}) in a 22Rv1-derived xenograft model. These data suggest that compound (R)-12 is a promising lead compound for the development of a new class of therapeutics for the treatment of CRPC.",
keywords = "3,5-Dimethylisoxazole, BRD4, Bromodomain inhibitor, Prostate cancer",
author = "Xiaoqian Xue and Yan Zhang and Chao Wang and Maofeng Zhang and Qiuping Xiang and Junjian Wang and Anhui Wang and Chenchang Li and Cheng Zhang and Lingjiao Zou and Rui Wang and Shuang Wu and Yongzhi Lu and Hongwu Chen and Ke Ding and Guohui Li and Yong Xu",
year = "2018",
month = "5",
day = "25",
doi = "10.1016/j.ejmech.2018.04.034",
language = "English (US)",
volume = "152",
pages = "542--559",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer

AU - Xue, Xiaoqian

AU - Zhang, Yan

AU - Wang, Chao

AU - Zhang, Maofeng

AU - Xiang, Qiuping

AU - Wang, Junjian

AU - Wang, Anhui

AU - Li, Chenchang

AU - Zhang, Cheng

AU - Zou, Lingjiao

AU - Wang, Rui

AU - Wu, Shuang

AU - Lu, Yongzhi

AU - Chen, Hongwu

AU - Ding, Ke

AU - Li, Guohui

AU - Xu, Yong

PY - 2018/5/25

Y1 - 2018/5/25

N2 - The bromodomain and extra-terminal proteins (BET) have emerged as promising therapeutic targets for the treatment of castration-resistant prostate cancer (CRPC). We report the design, synthesis and evaluation of a new series of benzoxazinone-containing 3,5-dimethylisoxazole derivatives as selective BET inhibitors. One of the new compounds, (R)-12 (Y02234), binds to BRD4(1) with a Kd value of 110 nM and blocks bromodomain and acetyl lysine interactions with an IC50 value of 100 nM. It also exhibits selectivity for BET over non-BET bromodomain proteins and demonstrates reasonable anti-proliferation and colony formation inhibition effect in prostate cancer cell lines such as 22Rv1 and C4-2B. The BRD4 inhibitor (R)-12 also significantly suppresses the expression of ERG, Myc and AR target gene PSA at the mRNA level in prostate cancer cells. Treatment with (R)-12 significantly suppresses the tumor growth of prostate cancer (TGI = 70%) in a 22Rv1-derived xenograft model. These data suggest that compound (R)-12 is a promising lead compound for the development of a new class of therapeutics for the treatment of CRPC.

AB - The bromodomain and extra-terminal proteins (BET) have emerged as promising therapeutic targets for the treatment of castration-resistant prostate cancer (CRPC). We report the design, synthesis and evaluation of a new series of benzoxazinone-containing 3,5-dimethylisoxazole derivatives as selective BET inhibitors. One of the new compounds, (R)-12 (Y02234), binds to BRD4(1) with a Kd value of 110 nM and blocks bromodomain and acetyl lysine interactions with an IC50 value of 100 nM. It also exhibits selectivity for BET over non-BET bromodomain proteins and demonstrates reasonable anti-proliferation and colony formation inhibition effect in prostate cancer cell lines such as 22Rv1 and C4-2B. The BRD4 inhibitor (R)-12 also significantly suppresses the expression of ERG, Myc and AR target gene PSA at the mRNA level in prostate cancer cells. Treatment with (R)-12 significantly suppresses the tumor growth of prostate cancer (TGI = 70%) in a 22Rv1-derived xenograft model. These data suggest that compound (R)-12 is a promising lead compound for the development of a new class of therapeutics for the treatment of CRPC.

KW - 3,5-Dimethylisoxazole

KW - BRD4

KW - Bromodomain inhibitor

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85047016155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047016155&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2018.04.034

DO - 10.1016/j.ejmech.2018.04.034

M3 - Article

C2 - 29758518

AN - SCOPUS:85047016155

VL - 152

SP - 542

EP - 559

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -